Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2015, Article ID 358263, 10 pages
http://dx.doi.org/10.1155/2015/358263
Review Article

A Neurologist’s Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease

1Research School of Biology, Australian National University, Acton, Canberra, ACT 2601, Australia
2Neurodegeneration Research Group, Garvan Institute, 384 Victoria Street, Sydney, NSW 2010, Australia

Received 21 April 2015; Accepted 21 May 2015

Academic Editor: Ariel Martinez

Copyright © 2015 Ian A. Clark and Bryce Vissel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. A. Carswell, L. J. Old, R. L. Kassel, S. Green, N. Fiore, and B. Williamson, “An endotoxin-induced serum factor that causes necrosis of tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 72, no. 9, pp. 3666–3670, 1975. View at Publisher · View at Google Scholar · View at Scopus
  2. E. A. Carswell-Richards and B. D. Williamson, “A man of vision and the discovery of tumor necrosis factor,” Cancer immunity, vol. 12, p. 4, 2012. View at Google Scholar · View at Scopus
  3. V. Hachinski, G. A. Donnan, P. B. Gorelick et al., “Stroke: working toward a prioritized world agenda,” Stroke, vol. 41, pp. 1084–1099, 2010. View at Publisher · View at Google Scholar
  4. W. S. T. Griffin, “Perispinal etanercept: potential as an Alzheimer therapeutic,” Journal of Neuroinflammation, vol. 5, no. 3, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. T. A. Ignatowski, R. N. Spengler, K. M. Dhandapani, H. Folkersma, R. F. Butterworth, and E. Tobinick, “Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence,” CNS Drugs, vol. 28, pp. 679–697, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. T. A. Ignatowski, R. N. Spengler, and E. Tobinick, “Authors' reply to Whitlock: perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence,” CNS Drugs, vol. 28, no. 12, pp. 1207–1213, 2014. View at Publisher · View at Google Scholar
  7. S. D. Quistad, A. Stotland, K. L. Barott et al., “Evolution of TNF-induced apoptosis reveals 550 My of functional conservation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 26, pp. 9567–9572, 2014. View at Publisher · View at Google Scholar
  8. S. Hong, R. Li, Q. Xu, C. J. Secombes, and T. Wang, “Two types of TNF-α exist in teleost fish: phylogeny, expression, and bioactivity analysis of type-II TNF-α3 in rainbow trout Oncorhynchus mykiss,” The Journal of Immunology, vol. 191, no. 12, pp. 5959–5972, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. F. W.-S. Lam, S.-Y. Wu, S.-J. Lin et al., “The expression of two novel orange-spotted grouper (Epinephelus coioides) TNF genes in peripheral blood leukocytes, various organs, and fish larvae,” Fish and Shellfish Immunology, vol. 30, no. 2, pp. 618–629, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. González-Stegmaier, A. Romero, A. Estepa, J. Montero, V. Mulero, and L. Mercado, “Effects of recombinant flagellin B and its ND1 domain from Vibrio anguillarum on macrophages from gilthead seabream (Sparus aurata L.) and rainbow trout (Oncorhynchus mykiss, W.),” Fish & Shellfish Immunology, vol. 42, no. 1, pp. 144–152, 2015. View at Publisher · View at Google Scholar
  11. L. Vitkovic, J. Bockaert, and C. Jacque, “‘Inflammatory’ cytokines: neuromodulators in normal brain?” Journal of Neurochemistry, vol. 74, no. 2, pp. 457–471, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. T. A. Ignatowski and R. N. Spengler, “Tumor necrosis factor-α: presynaptic sensitivity is modified after antidepressant drug administration,” Brain Research, vol. 665, no. 2, pp. 293–299, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Kato, H. Liu, S.-I. Kikuchi, R. R. Myers, and V. I. Shubayev, “Immediate anti-tumor necrosis factor-α (etanercept) therapy enhances axonal regeneration after sciatic nerve crush,” Journal of Neuroscience Research, vol. 88, no. 2, pp. 360–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Gavaldà, H. Gutierrez, and A. M. Davies, “Developmental regulation of sensory neurite growth by the tumor necrosis factor superfamily member LIGHT,” Journal of Neuroscience, vol. 29, no. 6, pp. 1599–1607, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Gutierrez, L. Kisiswa, G. W. O'Keeffe, M. J. Smithen, S. Wyatt, and A. M. Davies, “Regulation of neurite growth by tumour necrosis superfamily member RANKL,” Open Biology, vol. 3, Article ID 120150, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. A. Wheeler, D. L. Heffner, S. Kim et al., “TNF-α/TNFR1 signaling is required for the development and function of primary nociceptors,” Neuron, vol. 82, no. 3, pp. 587–602, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. K. R. L. Schmitt, F. Boato, A. Diestel et al., “Hypothermia-induced neurite outgrowth is mediated by tumor necrosis factor-alpha,” Brain Pathology, vol. 20, no. 4, pp. 771–779, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Meissner, N. P. Visanji, M. A. Momen, R. Feng, and B. M. Francis, “Tumor necrosis factor-alpha underlies loss of cortical dendritic spine density in a mouse model of congestive heart failure,” Journal of the American Heart Association, 2015. View at Publisher · View at Google Scholar
  19. B. Liu, B. Zupan, E. Laird et al., “Maternal hematopoietic TNF, via milk chemokines, programs hippocampal development and memory,” Nature Neuroscience, vol. 17, no. 1, pp. 97–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Marin and J. Kipnis, “Learning and memory... and the immune system,” Learning and Memory, vol. 20, no. 10, pp. 601–606, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Pickering, D. Cumiskey, and J. J. O'Connor, “Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system,” Experimental Physiology, vol. 90, no. 5, pp. 663–670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. R. Ferguson, R. N. Christensen, J. C. Gensel et al., “Cell death after spinal cord injury is exacerbated by rapid TNFα-induced trafficking of GluR2-lacking AMPARs to the plasma membrane,” The Journal of Neuroscience, vol. 28, no. 44, pp. 11391–11400, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Stellwagen and R. C. Malenka, “Synaptic scaling mediated by glial TNF-α,” Nature, vol. 440, no. 7087, pp. 1054–1059, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Becker, N. Zahn, T. Deller, and A. Vlachos, “Tumor necrosis factor alpha maintains denervation-induced homeostatic synaptic plasticity of mouse dentate granule cells,” Frontiers in Cellular Neuroscience, vol. 7, article no. 257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Cumiskey, M. P. Butler, P. N. Moynagh, and J. J. O'Connor, “Evidence for a role for the group I metabotropic glutamate receptor in the inhibitory effect of tumor necrosis factor-alpha on long-term potentiation,” Brain Research, vol. 1136, no. 1, pp. 13–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Bernardino, F. Agasse, B. Silva, R. Ferreira, S. Grade, and J. O. Malva, “Tumor necrosis factor-α modulates survival, proliferation, and neuronal differentiation in neonatal subventricular zone cell cultures,” Stem Cells, vol. 26, no. 9, pp. 2361–2371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Russo, S. Barlati, and F. Bosetti, “Effects of neuroinflammation on the regenerative capacity of brain stem cells,” Journal of Neurochemistry, vol. 116, no. 6, pp. 947–956, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Chen and T. D. Palmer, “Differential roles of TNFR1 and TNFR2 signaling in adult hippocampal neurogenesis,” Brain, Behavior, and Immunity, vol. 30, pp. 45–53, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Sánchez-Alcázar, E. Schneider, M. A. Martínez et al., “Tumor necrosis factor-α increases the steady-state reduction of cytochrome b of the mitochondrial respiratory chain in metabolically inhibited L929 cells,” The Journal of Biological Chemistry, vol. 275, no. 18, pp. 13353–13361, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Zhan, G. Q. Cai, A. Zheng et al., “Tumor necrosis factor-alpha regulates the Hypocretin system via mRNA degradation and ubiquitination,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1812, no. 4, pp. 565–571, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. I. A. Clark and B. Vissel, “Inflammation-sleep interface in brain disease: TNF, insulin, orexin,” Journal of Neuroinflammation, vol. 11, article 51, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. K. M. Park, D. I. Yule, and W. J. Bowers, “Tumor necrosis factor-α potentiates intraneuronal Ca2+ signaling via regulation of the inositol 1,4,5-trisphosphate receptor,” Journal of Biological Chemistry, vol. 283, no. 48, pp. 33069–33079, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. I. A. Clark, A. C. Allison, and F. E. Cox, “Protection of mice against Babesia, and Plasmodium with BCG,” Nature, vol. 259, no. 5541, pp. 309–311, 1976. View at Publisher · View at Google Scholar · View at Scopus
  34. I. A. Clark, “Does endotoxin cause both the disease and parasite death in acute malaria and babesiosis?” The Lancet, vol. 2, no. 8080, pp. 75–77, 1978. View at Google Scholar · View at Scopus
  35. I. A. Clark, J.-L. Virelizier, E. A. Carswell, and P. R. Wood, “Possible importance of macrophage-derived mediators in acute malaria,” Infection and Immunity, vol. 32, no. 3, pp. 1058–1066, 1981. View at Google Scholar · View at Scopus
  36. I. A. Clark, “How TNF was recognized as a key mechanism of disease,” Cytokine and Growth Factor Reviews, vol. 18, no. 3-4, pp. 335–343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. B. B. Aggarwal, W. J. Kohr, P. E. Hass et al., “Human tumor necrosis factor: production, purification, and characterization,” The Journal of Biological Chemistry, vol. 260, no. 4, pp. 2345–2354, 1985. View at Google Scholar · View at Scopus
  38. J. Vilcek, “First demonstration of the role of TNF in the pathogenesis of disease,” Journal of Immunology, vol. 181, no. 1, pp. 5–6, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Beutler, I. W. Milsark, and A. C. Cerami, “Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin,” Science, vol. 229, no. 4716, pp. 869–871, 1985. View at Publisher · View at Google Scholar · View at Scopus
  40. I. A. Clark, L. M. Alleva, A. C. Mills, and W. B. Cowden, “Pathogenesis of malaria and clinically similar conditions,” Clinical Microbiology Reviews, vol. 17, no. 3, pp. 509–539, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. G. A. W. Rook, J. Taverne, C. Leveton, and J. Steele, “The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis,” Immunology, vol. 62, no. 2, pp. 229–234, 1987. View at Google Scholar · View at Scopus
  42. I. A. Clark and W. B. Cowden, “Is TNF a key to acute infectious illness?” Today's Life Science, vol. 1, no. 1, pp. 26–29, 1989. View at Google Scholar · View at Scopus
  43. S. Raziuddin, R. E. Abdalla, E. H. El-Awad, and M. Al-Janadi, “Immunoregulatory and proinflammatory cytokine production in visceral and cutaneous leishmaniasis,” Journal of Infectious Diseases, vol. 170, no. 4, pp. 1037–1040, 1994. View at Publisher · View at Google Scholar · View at Scopus
  44. R. L. Peper and H. van Campen, “Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia,” Microbial Pathogenesis, vol. 19, no. 3, pp. 175–183, 1995. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. A. Bhutta, N. Mansoorali, and R. Hussain, “Plasma cytokines in paediatric typhoidal salmonellosis: correlation with clinical course and outcome,” Journal of Infection, vol. 35, no. 3, pp. 253–256, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Arsenijevic, L. Girardier, J. Seydoux, H. R. Chang, and A. G. Dulloo, “Altered energy balance and cytokine gene expression in a murine model of chronic infection with Toxoplasma gondii,” American Journal of Physiology—Endocrinology and Metabolism, vol. 272, no. 5, pp. E908–E917, 1997. View at Google Scholar · View at Scopus
  47. A. Nakane, K. Yamada, S. Hasegawa et al., “Endogenous cytokines during a lethal infection with Listeria monocytogenes in mice,” FEMS Microbiology Letters, vol. 175, no. 1, pp. 133–142, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. D. R. Spriggs, M. L. Sherman, H. Michie et al., “Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study,” Journal of the National Cancer Institute, vol. 80, no. 13, pp. 1039–1044, 1988. View at Publisher · View at Google Scholar · View at Scopus
  49. C. J. Fisher Jr., J. M. Agosti, S. M. Opal et al., “Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein,” The New England Journal of Medicine, vol. 334, no. 26, pp. 1697–1702, 1996. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Waage, A. Halstensen, and T. Espevik, “Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease,” The Lancet, vol. 1, no. 8529, pp. 355–357, 1987. View at Google Scholar · View at Scopus
  51. R. E. Coxon, D. Fekade, K. Knox et al., “The effect of antibody against TNFα on cytokine response in Jarisch-Herxheimer reactions of louse-borne relapsing fever,” QJM, vol. 90, no. 3, pp. 213–221, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. D. Fekade, K. Knox, K. Hussein et al., “Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor α,” The New England Journal of Medicine, vol. 335, no. 5, pp. 311–315, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. L. Chatenoud, “OKT3-induced cytokine-release syndrome: preventive effect of anti-tumor necrosis factor monoclonal antibody,” Transplantation Proceedings, vol. 25, no. 2, pp. 47–51, 1993. View at Google Scholar · View at Scopus
  54. J. D. Eason, M. Pascual, S. Wee et al., “Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome,” Transplantation, vol. 61, no. 2, pp. 224–228, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. E. Holler, H. J. Kolb, J. Mittermüller et al., “Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor α (TNFα) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFα (MAK 195F),” Blood, vol. 86, no. 3, pp. 890–899, 1995. View at Google Scholar · View at Scopus
  56. D. A. Jacobsohn and G. B. Vogelsang, “Novel pharmacotherapeutic approaches to prevention and treatment of GVHD,” Drugs, vol. 62, no. 6, pp. 879–889, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. A. M. Reimold, “New indications for treatment of chronic inflammation by TNF-α blockade,” The American Journal of the Medical Sciences, vol. 325, no. 2, pp. 75–92, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Nathan and A. Ding, “Nonresolving inflammation,” Cell, vol. 140, no. 6, pp. 871–882, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. F. M. Brennan, D. Chantry, A. Jackson, R. Maini, and M. Feldmann, “Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis,” The Lancet, vol. 2, no. 8657, pp. 244–247, 1989. View at Google Scholar · View at Scopus
  60. P. Charles, M. J. Elliott, D. Davis et al., “Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis,” Journal of Immunology, vol. 163, no. 3, pp. 1521–1528, 1999. View at Google Scholar · View at Scopus
  61. R. N. Maini, “A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 13, supplement 12, pp. S35–S40, 1995. View at Google Scholar · View at Scopus
  62. M. Feldmann, F. M. Brennan, D. Chantry et al., “Cytokine production in the rheumatoid joint: implications for treatment,” Annals of the Rheumatic Diseases, vol. 49, no. 1, pp. 480–486, 1990. View at Google Scholar · View at Scopus
  63. M. J. Elliott, R. N. Maini, M. Feldmann et al., “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha,” Arthritis and Rheumatism, vol. 36, no. 12, pp. 1681–1690, 1993. View at Publisher · View at Google Scholar · View at Scopus
  64. M. J. Elliott, R. N. Maini, M. Feldmann et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis,” Lancet, vol. 344, no. 8930, pp. 1105–1110, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. L. G. Criscione and E. W. S. Clair, “Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases,” Current Opinion in Rheumatology, vol. 14, no. 3, pp. 204–211, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. C. J. Oh, K. M. Das, and A. B. Gottlieb, “Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions,” Journal of the American Academy of Dermatology, vol. 42, no. 5, pp. 829–830, 2000. View at Publisher · View at Google Scholar · View at Scopus
  67. T. R. Freeman and P. Piascik, “Monoclonal antibody approved for treatment of Crohn's disease,” Journal of the American Pharmaceutical Association, vol. 38, no. 6, pp. 770–772, 1998. View at Google Scholar · View at Scopus
  68. I. A. Clark, L. M. Alleva, and B. Vissel, “The roles of TNF in brain dysfunction and disease,” Pharmacology and Therapeutics, vol. 128, no. 3, pp. 519–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Tobinick, N. M. Kim, G. Reyzin, H. Rodriguez-Romanacce, and V. Depuy, “Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept,” CNS Drugs, vol. 26, no. 12, pp. 1051–1070, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Z. Feuerstein, T. Liu, and F. C. Barone, “Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha,” Cerebrovascular and Brain Metabolism Reviews, vol. 6, no. 4, pp. 341–360, 1994. View at Google Scholar · View at Scopus
  71. C. Jacque and J.-L. Tchelingerian, “New concepts on the role of cytokines in the central nervous system,” Revue Neurologique, vol. 150, no. 11, pp. 748–756, 1994. View at Google Scholar · View at Scopus
  72. B. Arvin, L. F. Neville, F. C. Barone, and G. Z. Feuerstein, “The role of inflammation and cytokines in brain injury,” Neuroscience and Biobehavioral Reviews, vol. 20, no. 3, pp. 445–452, 1996. View at Publisher · View at Google Scholar · View at Scopus
  73. E. Tarkowski, A.-M. Liljeroth, L. Minthon, A. Tarkowski, A. Wallin, and K. Blennow, “Cerebral pattern of pro- and anti-inflammatory cytokines in dementias,” Brain Research Bulletin, vol. 61, no. 3, pp. 255–260, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. M. M. Esiri, “The interplay between inflammation and neurodegeneration in CNS disease,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 4–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Eikelenboom, R. Veerhuis, E. van Exel, J. J. M. Hoozemans, A. J. M. Rozemuller, and W. A. van Gool, “The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence,” Current Alzheimer Research, vol. 8, no. 2, pp. 142–150, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. T. K. Howcroft, J. Campisi, G. B. Louis et al., “The role of inflammation in age-related disease,” Aging, vol. 5, no. 1, pp. 84–93, 2013. View at Google Scholar · View at Scopus
  77. E. Tobinick and S. Davoodifar, “Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients,” Current Medical Research and Opinion, vol. 20, no. 7, pp. 1075–1085, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. S. P. Cohen, N. Bogduk, A. Dragovich et al., “Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica,” Anesthesiology, vol. 110, no. 5, pp. 1116–1126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Ohtori, M. Miyagi, Y. Eguchi et al., “Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study,” Spine, vol. 37, no. 6, pp. 439–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. B. J. C. Freeman, G. L. Ludbrook, S. Hall et al., “Randomized, double-blind, placebo-controlled, trial of transforaminal epidural etanercept for the treatment of symptomatic lumbar disc herniation,” Spine, vol. 38, no. 23, pp. 1986–1994, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. T. Sainoh, S. Orita, K. Yamauchi et al., “Intradiscal administration of tumor necrosis factor-α inhibitor, etanercept, clinically Improves Intractable discogenic low back pain,” Global Spine Journal, vol. 04, 2014. View at Publisher · View at Google Scholar
  82. S. H. Horowitz, “Thrombolytic therapy in acute stroke: neurologists, get off your hands!,” Archives of Neurology, vol. 55, no. 2, pp. 155–157, 1998. View at Publisher · View at Google Scholar · View at Scopus
  83. C.-C. Chio, C.-H. Chang, C.-C. Wang et al., “Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α,” BMC Neuroscience, vol. 14, article 33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. B. H. Clausen, M. Degn, N. A. Martin et al., “Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia,” Journal of Neuroinflammation, vol. 11, article 203, 2014. View at Publisher · View at Google Scholar
  85. A. Abulrob, H. Sprong, P. Van Bergen en Henegouwen, and D. Stanimirovic, “The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells,” Journal of Neurochemistry, vol. 95, no. 4, pp. 1201–1214, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. Q.-H. Zhou, R. J. Boado, E. K.-W. Hui, J. Z. Lu, and W. M. Pardridge, “Brain-penetrating tumor necrosis factor decoy receptor in the mouse,” Drug Metabolism & Disposition, vol. 39, no. 1, pp. 71–76, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. R. K. Sumbria, R. J. Boado, and W. M. Pardridge, “Brain protection from stroke with intravenous TNFalpha decoy receptor-Trojan horse fusion protein,” Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 10, pp. 1933–1938, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. O. V. Batson, “The function of the vertebral veins and their role in the spread of metastases,” Annals of Surgery, vol. 112, no. 1, pp. 138–149, 1940. View at Google Scholar
  89. E. L. Tobinick, H. Gross, A. Weinberger, and H. Cohen, “TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study,” Medscape General Medicine, vol. 8, no. 2, article 25, 2006. View at Google Scholar · View at Scopus
  90. E. Tobinick, “Perispinal etanercept for neuroinflammatory disorders,” Drug Discovery Today, vol. 14, no. 3-4, pp. 168–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. E. Tobinick, “Perispinal etanercept: a new therapeutic paradigm in neurology,” Expert Review of Neurotherapeutics, vol. 10, no. 6, pp. 985–1002, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. P. H. Hashimoto, T. Gotow, T. Ichimura et al., “Visualization of the cerebrospinal fluid drainage into the Galen's vein,” Archivum Histologicum Japonicum, vol. 48, no. 2, pp. 173–181, 1985. View at Google Scholar · View at Scopus
  93. H. Biceroglu, S. Albayram, S. Ogullar et al., “Direct venous spinal reabsorption of cerebrospinal fluid: a new concept with serial magnetic resonance cisternography in rabbits Laboratory investigation,” Journal of Neurosurgery: Spine, vol. 16, no. 4, pp. 394–401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  94. E. Tobinick and C. P. Vega, “The cerebrospinal venous system: anatomy, physiology, and clinical implications,” MedGenMed Medscape General Medicine, vol. 8, article 53, 2006. View at Google Scholar · View at Scopus
  95. T.-S. Wen, D. C. Randall, and J. F. Zolman, “Protein accumulation in cerebrospinal fluid during-90° head-down tilt in rabbit,” Journal of Applied Physiology, vol. 77, no. 3, pp. 1081–1086, 1994. View at Google Scholar · View at Scopus
  96. E. L. Tobinick and H. Gross, “Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration,” Journal of Neuroinflammation, vol. 5, article 2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. E. Tobinick, “Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases,” CNS Drugs, vol. 25, no. 2, pp. 145–155, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. E. Tobinick, H. Rodriguez-Romanacce, A. Levine, T. A. Ignatowski, and R. N. Spengler, “Immediate neurological recovery following perispinal etanercept years after brain injury,” Clinical Drug Investigation, vol. 34, no. 5, pp. 361–366, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. D. Bohac, W. Burke, R. Cotter, J. Zheng, and J. Potter, “A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type,” Neurobiol Aging, vol. 23, supplement 1, pp. S1–S606, 2002, abstract 315. View at Google Scholar
  100. J. Butchart, L. Brook, V. Hopkins et al., “Etanercept in Alzheimer disease: a randomized, placebo-controlled, double-blind, phase 2 trial,” Neurology, vol. 84, no. 21, pp. 2161–2168, 2015. View at Publisher · View at Google Scholar
  101. A. Tuttolomondo, R. Pecoraro, and A. Pinto, “Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date,” Drug Design, Development and Therapy, vol. 8, pp. 2221–2238, 2014. View at Publisher · View at Google Scholar
  102. M. S. Dhamoon, Y. P. Moon, M. C. Paik et al., “Long-term functional recovery after first ischemic stroke: the Northern Manhattan Study,” Stroke, vol. 40, no. 8, pp. 2805–2811, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. Y. J. Alderazi and R. Bomprezzi, “Are randomized, blind clinical trials enough to guide individualized decisions for patients with neurologic diseases?” Neurology: Clinical Practice, vol. 4, no. 4, pp. 319–328, 2014. View at Publisher · View at Google Scholar
  104. D. Baeten and P. M. van Hagen, “Use of TNF blockers and other targeted therapies in rare refractory immune-mediated inflammatory diseases: evidence-based or rational?” Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2067–2073, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. S. J. Page, “Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept,” CNS Drugs, vol. 27, no. 5, pp. 395–397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. D. R. Whitlock, “Comment on: ‘perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence’,” CNS Drugs, vol. 28, no. 12, pp. 1205–1206, 2014. View at Publisher · View at Google Scholar
  107. J. E. Paramarta, L. de Rycke, C. A. Ambarus, P. P. Tak, and D. Baeten, “Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment,” Rheumatology, vol. 52, no. 10, pp. 1873–1878, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. N. Terrando, C. Monaco, D. Ma, B. M. J. Foxwell, M. Feldmannc, and M. Maze, “Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 47, pp. 20518–20522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. C. M. Wilson, M. W. Gaber, O. M. Sabek, J. A. Zawaski, and T. E. Merchant, “Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 3, pp. 934–941, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Kesler, M. Janelsins, D. Koovakkattu et al., “Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors,” Brain, Behavior, and Immunity, vol. 30, pp. S109–S116, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. M. D. Elfferich, P. J. Nelemans, R. W. Ponds, J. De Vries, P. A. Wijnen, and M. Drent, “Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-α treatment,” Respiration, vol. 80, no. 3, pp. 212–219, 2010. View at Publisher · View at Google Scholar · View at Scopus
  112. Y.-M. Chen, H.-H. Chen, J.-L. Lan, and D.-Y. Chen, “Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis,” Joint Bone Spine, vol. 77, no. 4, pp. 366–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Hess, R. Axmann, J. Rech et al., “Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3731–3736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Mussi, C. Bonifati, M. Carducci et al., “Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis,” Journal of Biological Regulators and Homeostatic Agents, vol. 11, no. 3, pp. 115–118, 1997. View at Google Scholar · View at Scopus
  115. U. Chaudhari, P. Romano, L. D. Mulcahy, L. T. Dooley, D. G. Baker, and A. B. Gottlieb, “Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial,” The Lancet, vol. 357, no. 9271, pp. 1842–1847, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. L. J. Van Eldik and W. S. T. Griffin, “S100β expression in Alzheimer's disease: Relation to neuropathology in brain regions,” Biochimica et Biophysica Acta, vol. 1223, no. 3, pp. 398–403, 1994. View at Google Scholar · View at Scopus
  117. J. E. Paramarta and D. Baeten, “Spondyloarthritis: from unifying concepts to improved treatment,” Rheumatology, vol. 53, no. 9, pp. 1547–1559, 2014. View at Publisher · View at Google Scholar
  118. E. Holler, H. J. Kolb, R. Hintermeier-Knabe et al., “Role of tumor necrosis factor-alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation,” Transplantation Proceedings, vol. 25, no. 1, pp. 1234–1236, 1993. View at Google Scholar · View at Scopus
  119. T. A. Ignatowski, W. C. Covey, P. R. Knight, C. M. Severin, T. J. Nickola, and R. N. Spengler, “Brain-derived TNFalpha mediates neuropathic pain,” Brain Research, vol. 841, no. 1-2, pp. 70–77, 1999. View at Publisher · View at Google Scholar · View at Scopus
  120. W. C. Covey, T. A. Ignatowski, P. R. Knight, and R. N. Spengler, “Brain-derived TNFα: involvement in neuroplastic changes implicated in the conscious perception of persistent pain,” Brain Research, vol. 859, no. 1, pp. 113–122, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. W. C. Covey, T. A. Ignatowski, A. E. Renauld, P. R. Knight, N. D. Nader, and R. N. Spengler, “Expression of neuron-associated tumor necrosis factor alpha in the brain is increased during persistent pain,” Regional Anesthesia and Pain Medicine, vol. 27, no. 4, pp. 357–366, 2002. View at Publisher · View at Google Scholar · View at Scopus
  122. E. L. Tobinick, “Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports,” Clinical Therapeutics, vol. 25, no. 8, pp. 2279–2288, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. E. Gerard, R. N. Spengler, A. C. Bonoiu et al., “Chronic constriction injury-induced nociception is relieved by nanomedicine-mediated decrease of rat hippocampal tumor necrosis factor,” Pain, 2015. View at Publisher · View at Google Scholar
  124. J.-Q. Shi, W. Shen, J. Chen et al., “Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains,” Brain Research, vol. 1368, pp. 239–247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. A. S. Harms, C. J. Barnum, K. A. Ruhn et al., “Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of parkinson's disease,” Molecular Therapy, vol. 19, no. 1, pp. 46–52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. H.-Y. Hsiao, Y.-C. Chen, H.-M. Chen, P.-H. Tu, and Y. Chern, “A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in huntington's disease,” Human Molecular Genetics, vol. 22, no. 9, Article ID ddt036, pp. 1826–1842, 2013. View at Publisher · View at Google Scholar · View at Scopus
  127. K. Belarbi, T. Jopson, D. Tweedie et al., “TNF-α protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation,” Journal of Neuroinflammation, vol. 9, article 23, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Pribiag and D. Stellwagen, “Neuroimmune regulation of homeostatic synaptic plasticity,” Neuropharmacology, vol. 78, pp. 13–22, 2014. View at Publisher · View at Google Scholar
  129. E. Tobinick, “Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in alzheimer's disease,” Current Alzheimer Research, vol. 9, no. 1, pp. 99–109, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Pappata, M. Levasseur, R. N. Gunn et al., “Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK11195,” Neurology, vol. 55, no. 7, pp. 1052–1054, 2000. View at Publisher · View at Google Scholar · View at Scopus
  131. A. F. Ramlackhansingh, D. J. Brooks, R. J. Greenwood et al., “Inflammation after trauma: microglial activation and traumatic brain injury,” Annals of Neurology, vol. 70, no. 3, pp. 374–383, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. V. E. Johnson, J. E. Stewart, F. D. Begbie, J. Q. Trojanowski, D. H. Smith, and W. Stewart, “Inflammation and white matter degeneration persist for years after a single traumatic brain injury,” Brain, vol. 136, no. 1, pp. 28–42, 2013. View at Publisher · View at Google Scholar · View at Scopus